Nuveen LLC Acquires Shares of 150,314 4D Molecular Therapeutics, Inc. $FDMT

Key Points

• Nuveen LLC has invested approximately $486,000 in 4D Molecular Therapeutics, acquiring 150,314 shares, which accounts for 0.32% of the company's total shares.
• Brokerages have provided mixed ratings for 4D Molecular Therapeutics, with eight analysts rating it as "Buy", a consensus target price of $30.40, and significant price targets varying from as high as $51 to as low as $25.
• 4D Molecular Therapeutics reported a substantial loss of ($0.98) per share for the last quarter, falling short of the consensus estimate and reflecting a challenging financial position with a negative net margin of over 594,000%.

Nuveen LLC bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 150,314 shares of the company's stock, valued at approximately $486,000. Nuveen LLC owned about 0.32% of 4D Molecular Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Millennium Management LLC increased its holdings in shares of 4D Molecular Therapeutics by 1,607.1% in the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after buying an additional 1,337,497 shares during the last quarter. Federated Hermes Inc. grew its position in 4D Molecular Therapeutics by 33,131.8% in the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after acquiring an additional 1,246,419 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in 4D Molecular Therapeutics by 2,084.5% in the fourth quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company's stock worth $2,500,000 after acquiring an additional 428,285 shares in the last quarter. Two Sigma Investments LP increased its stake in 4D Molecular Therapeutics by 196.3% during the fourth quarter. Two Sigma Investments LP now owns 313,993 shares of the company's stock worth $1,749,000 after acquiring an additional 208,021 shares during the last quarter. Finally, Bank of America Corp DE raised its position in 4D Molecular Therapeutics by 49.8% during the fourth quarter. Bank of America Corp DE now owns 384,880 shares of the company's stock valued at $2,144,000 after purchasing an additional 127,885 shares during the period. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock traded down $0.03 during mid-day trading on Wednesday, hitting $6.94. 624,832 shares of the stock traded hands, compared to its average volume of 678,483. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.23 and a 52-week high of $17.41. The stock has a market cap of $324.10 million, a P/E ratio of -1.97 and a beta of 2.86. The stock's fifty day moving average is $5.58 and its two-hundred day moving average is $4.32.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. As a group, equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Roth Capital cut their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Saturday, August 30th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.